Richard Francis Riedel

Journal Article J Clin Oncol · June 2026 We previously reported initial results of the pivotal phase II trial of atezolizumab for patients with alveolar soft part sarcoma (ASPS; ClinicalTrials.gov identifier: NCT03141684). Here, we report on three additional years of observation. Fifty-three pati ... Full text Link to item Cite

Multi-Omic Landscape of Gastrointestinal Stromal Tumors in a Real-World Patient Cohort of 1,427 Cases.

Journal Article Clin Cancer Res · April 30, 2026 PURPOSE: Gastrointestinal stromal tumor (GIST) is a genomically-driven neoplasm with a genetic profile that determines the clinical course of the disease. However, currently available molecular data is limited due to the rarity of the disease and does not ... Full text Link to item Cite

Reply to: In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors.

Journal Article J Clin Oncol · April 24, 2026 Full text Link to item Cite

View All Publications

Recent Grants

A Phase 1a/1b Study of the Safety, Pharmacokinetics, and Antitumor Activity of the Oral Menin Inhibitor Ziftomenib in Combination with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors (GIST) After Imatinib Failure

Clinical TrialPrincipal Investigator · Awarded by Kura Oncology, Inc. · 2025 - 2030

A Phase II, Multi-centre, Randomised, Double-blind, Group Comparator Trial to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Patients with Tenosynovial Giant Cell Tumour,

Clinical TrialPrincipal Investigator · Awarded by SynOx Therapeutics Ltd · 2025 - 2030

A Multicenter, Randomized, Phase 3 Study to Assess the Efficacy and Safety of INtratumorally Administered INT230-6 (SHAO, VINblastine, CIsplatin) Compared With US Standard of Care in Adult Participants With Locally Recurrent, InoperaBLE,orMetastatic

Clinical TrialPrincipal Investigator · Awarded by Intensity Therapeutics, Inc. · 2024 - 2029

View All Grants

Education

Thomas Jefferson University · 2000 M.D.